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ABSTRACT
Purpose: To summarize existing knowledge and to understand individual response to radiation
exposure, the MELODI Association together with CONCERT European Joint Programme has organ-
ized a workshop in March 2018 on radiation sensitivity and susceptibility.
Methods: The workshop reviewed the current evidence on this matter, to inform the MELODI
Strategic Research Agenda (SRA), to determine social and scientific needs and to come up with
recommendations for suitable and feasible future research initiatives to be taken for the benefit of
an improved medical diagnosis and treatment as well as for radiation protection.
Results: The present paper gives an overview of the current evidence in this field, including
potential effect modifiers such as age, gender, genetic profile, and health status of the exposed
population, based on clinical and epidemiological observations.
Conclusion: The authors conclude with the following recommendations for the way forward in
radiation research: (a) there is need for large (prospective) cohort studies; (b) build upon existing
radiation research cohorts; (c) use data from well-defined cohorts with good exposure assessment
and biological material already collected; (d) focus on study quality with standardized data collec-
tion and reporting; (e) improve statistical analysis; (f) cooperation between radiobiology and epi-
demiology; and (g) take consequences of radiosensitivity and radiosusceptibility into account.
Abbreviations: CLL: chronic lymphatic leukemia; CT: computed tomography; CTCAE: common ter-
minology criteria for adverse events; DICOM: digital imaging and communications in medicine;
DVH: dose-volume-histogram; EORTC: European Organization for Research and Treatment of
Cancer; EPIC: expanded prostate cancer index composite; EUD: equivalent uniform dose;
EURAMED: European Alliance for Medical Radiation Protection Research; FACIT: Functional
Assessment of Chronic Illness Therapy; FACT: Functional Assessment of Cancer Therapy; HLEG:
High Level Expert Group; ICRP: The International Commission on Radiological Protection (ICRP);
IMRT: intensity modulated radiotherapy; IR: ionizing radiation; LENT-SOMA: Late Effects in Normal
Tissue – Subjective, Objective, Management, Analytic criteria; MELODI: Multidisciplinary European
Low Dose Initiative; MRI: magnetic resonance imaging; NTCP: normal tissue complication probabil-
ity; RgC: Radiogenomics Consortium; RR: relative risk; RTOG/EORTC: Radiation Therapy Oncology
Group and the European Organization for Research and Treatment of Cancer criteria; SRA:
Strategic Research Agenda; STAT: Standardized Total Average Toxicity score
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In 2007, the European Commission set up a High Level
Expert Group (HLEG) to help improve the knowledge on
low dose ionising radiation health effects and radiation pro-
tection. Low dose is defined as up to 100 mGy of low-LET
radiation (Wakeford and Tawn 2010; UNSCEAR 2012a,
2012b) and, for the purposes of this review, doses between
0.1 and 1Gy are referred as ‘moderate doses’, and those
above 1Gy as ‘high doses’. HLEG came up with the follow-
ing recommendations: In addition to the necessity to deal
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with existing uncertainties in radiation protection, the areas
of individual radiation sensitivity and radiation-induced
(non-)cancer effects need to be explored (HLEG 2009). The
Multidisciplinary European Low Dose Initiative (MELODI)
Association was founded in order to promote scientific
work on all these issues, and as a first step a European
research network (see the DoReMi project 2010–2015,
Averbeck et al. 2018) was launched to advance knowledge
and understanding of the health effects of radiation and pro-
vide a basis for improved radiation protection.
In early 2018, MELODI carried out an analysis of know-
ledge gaps in low dose health risk evaluation, by reflecting
the topics and outcome of the FP6 and FP7 Euratom proj-
ects. While all projects have made progress in building the
evidence base, there remain areas where additional work
could be beneficial. To understand the potential impact of
individual susceptibility on radiation-induced health effects,
MELODI concluded that there is need for (a) studies that
lead to the identification and validation of biomarkers of
disease risk and/or susceptibility; (b) studies that identify
and validate cohorts suitable for molecular/biomarker epi-
demiological studies; (c) studies of tissue level effects and
the role of individual differences in tissue architecture that
impact on the susceptibility to radiogenic diseases; and (d)
for studies that potentially lead to the identification of bio-
markers of resistance to radiation health effects.
Although there is a large number of biological and epi-
demiological studies investigating the health effects after
exposure to low dose ionizing radiation, results are not always
consistent and a clear understanding of the observations from
experimental and epidemiological results is still missing.
One possible explanation (or hypothesis) among others
(e.g. differing length of follow-up and statistical power or dif-
ferent data quality between studies) is the existence of indi-
vidual sensitivity to radiation which may explain
heterogeneous results between epidemiological studies. Thus,
further scientifically based information about the extent of
variability in individual reaction to radiation exposure should
be obtained. To summarize existing knowledge and to stimu-
late further research in this matter, the MELODI Association
together with CONCERT European Joint Program has organ-
ized a specific workshop in March 2018 on individual radi-
ation sensitivity/susceptibility. The workshop reviewed the
current evidence on this matter, to inform the MELODI
Strategic Research Agenda (SRA), to determine social and sci-
entific needs and to come up with recommendations for suit-
able and feasible future research initiatives to be taken for the
benefit of an improved medical diagnosis and treatment as
well as for radiation protection.
The present paper gives an overview of the current evi-
dence in this domain, based on clinical and epidemiological
observations. The overview includes the frequency of
adverse effects, the dependency on certain radiation parame-
ters and potential effect modifiers such as life-style, age, gen-
der, genetic profile, and health status of the exposed
population. The main focus in this workshop was on health
effects after exposure to low dose radiation such as occupa-
tional exposure, exposure from diagnostic procedure and
environmental exposure. Additionally, individual response to
radiation in patient cohorts exposed to high radiotherapy
doses were also discussed as those results contribute to the
understanding of low dose effects in several regards. Organs
outside the radiotherapy target tissue may be exposed to low
or medium doses through scatter from the RT beam, imag-
ing or other radiation exposure. Further, observations in
populations exposed to high dose (radiotherapy) can help to
evaluate the dose-response relationship.
1.1. Terminology
In general, two types of radiation effects can be distin-
guished: so-called deterministic effects and stochastic effects.
The mechanisms underlying these two phenomena are
thought to be quite different, deterministic effects arising
from cell killing or malfunction of cells, and stochastic
effects arising from clonal expansion of mutated cells (Hall
and Giaccia 2006; ICRP 2007). Deterministic effects gener-
ally have a threshold dose below which the effects do not
manifest and, above this threshold, the effect becomes more
severe as the dose increases. It is generally thought that
there is no threshold dose for the stochastic effects and their
probability but not severity increases with dose.
Traditionally, stochastic effects include cancer and hereditary
effects. We acknowledge that the division of radiation effects
into deterministic and stochastic categories is not so clear
cut (Hamada et al. 2018), especially as the threshold doses
for some effects previously considered as deterministic such
as lens opacities and vascular diseases are much lower than
previously thought and there may even be no threshold (e.g.
Averbeck et al. 2018; Thome et al. 2018). For cataracts, there
might be a high dose non-stochastic type and a low dose
type of cataracts with long latency effect that causes cata-
racts to occur earlier in life than if not exposed to radiation.
The International Commission on Radiological Protection
(ICRP) has recently adopted a new term ‘tissue reactions’
for the non-cancer effects of deterministic nature (ICRP
2007; 2012).
Variation in radiation sensitivity refers here to differences
in the threshold for developing tissue reactions induced by
ionizing radiation. It has been described in the first decade
of the 20th century (as summarized by Foray et al. 2012).
Radiation susceptibility defined as the proneness to radi-
ation-induced cancers was first reported during the same
period (Frieben 1902). Radiosensitivity and radiosusceptibil-
ity are regarded here as two different types of individual
responses to ionizing radiation. At least up to date, there are
no studies clearly showing that radiation sensitive individu-
als are also at higher risk for stochastic effects, that is radi-
ation susceptible. Accordingly, throughout the paper, we
propose to use the term radiation sensitivity/radiosensitivity
for individuals who are at higher risk for early or late reac-
tions in normal tissue after radiation and the term radiation
susceptibility/radiosusceptibility for individuals who exhibit
higher cancer risk after radiation than the general popula-
tion (Foray et al. 2016). Radiosensitivity is particularly rele-
vant in the clinical setting (e.g. after radiotherapy), whereas
2 P. SEIBOLD ET AL.
radiosusceptibility is an important issue for both low dose
and high dose radiation exposure. We acknowledge though
that the distinction into the two terms ‘radiation sensitivity’
and ‘radiation susceptibility’ is under discussion (e.g. Wojcik
et al. 2018).
Radiation-induced risk of health outcomes is not neces-
sarily similar for all individuals. Risk is defined as the prob-
ability of an event in a given population and time span
(Porta 2014). The concept in itself implies a probability of
an event, and risks that are not one or zero are not neces-
sarily homogeneous within the population, that is some sub-
jects are affected and others are not. For an individual, the
outcome is either experienced or not. It is a dichotomy, that
is the condition is absent or present, and not a degree of
probability.
Effect modification is defined as variation in the magni-
tude of effect across the levels of another factor that means
that the effect of the exposure is not similar in the entire
study population, but another factor alters the dose effect.
In statistics, this phenomenon is called interaction. For radi-
ation-induced health risks, this means heterogeneity or non-
uniformity of the dose effect. Effect modification is analyzed
by dividing the study population into subgroups, and then
examining if the effect of the exposure is comparable
between the various strata (Rothman et al. 2012). The over-
all difference between the sub-groups is evaluated using an
interaction term, testing the hypothesis of uniformity of
the effect.
There is one study that demonstrated in mice that rela-
tive risk can be applied to different backgrounds (Storer and
Fry 1995), but this is still debatable for example, in terms of
generalizability (NRC 2006).
1.2. Why is the topic important?
Although much is known about radiation risks, still consid-
erable uncertainty exists in their quantification (UNSCEAR
2012b). In order to reduce these uncertainties, it is import-
ant to improve and continue epidemiological studies of
health effects from exposures to ionizing radiation, and to
develop methods to quantify and combine the various sour-
ces of uncertainties. Such uncertainties include for example,
impact of population selection, exposure assessment, health
outcome assessment, study design, confounding factors, stat-
istical methods and model uncertainty and hypothesis of
baseline stability over time (UNSCEAR 2019). ICRP recog-
nizes variation in sensitivity and variability in radiation-
related health risk. In 1999, the ICRP issued publication
‘Genetic susceptibility to cancer’ (ICRP 1998). In UK, the
Advisory Group on Ionising Radiation published a report
on human radiosensitivity (HPA 2013). At present, there is
insufficient information on the influence of individual radi-
ation responses on health risk estimates. In particular, sound
data on responses to radiation at different dose levels, dose
rates and with radiation of different qualities are often not
sufficient to estimate risk without substantial uncertainties
in many exposure situations. Thus, a well-integrated multi-
disciplinary research (including mechanistic studies) is
required to elucidate the extent of variation of radiation-
related sensitivity and susceptibility and the factors contribu-
ting to this variation. The individual response to ionizing
radiation has been identified by MELODI and subsequently
also by EURAMED as an important issue because of the
high probability that the people concerned by an abnormal
response deserve more attention and radiological protection
than normal responders. The abnormal response was ini-
tially named ‘radiosensitivity’ and mentioned as a priority in
the SRA of MELODI. Implications for radiation protection
are not straightforward and include several ethical consider-
ations. The first question is how to identify those that
might be sensitive to radiation, how large is the variation in
sensitivity in population and who might be in need of add-
itional protections. The identification of variability in the
response to ionizing radiation raises public health, socio-
economic and ethical issues which should be addressed.
Radiosusceptibility is unlikely to be characterized by a single
modifying factor within a multivariate risk model, nor exist
as a trait dividing the population into simple radiosusceptible
and radioresistant groups. Tailoring of medical treatments
and radiation protection strategies at an individual level is a
current trend. However, testing of individual IR responses of
low-dose occupationally exposed individuals is questionable
(Hamada et al. 2018). In the clinical context, translating the
results into clinical practice will require decision support to
guide radiation oncologists. The goal is not to strictly specify
treatment, but to indicate possible options, help guide deci-
sion-making and confirm eligibility for enrollment in clinical
trials. Individuals identified with severe radiation sensitivity
will be exceedingly rare, such that the most relevant sub-
group is the larger population of patients with moderate sen-
sitivity and a less-certain outcome. One of the areas defined
by the MELODI Strategic Research Agenda that requires fur-
ther research is the development and validation of biomarkers
for exposure, early and late effects for cancer and non-cancer
diseases. This part including the biological mechanisms is
summarized by Gomolka et al. (2019) and Averbeck et al.
(2019) in this Special Issue.
Up to 20% of patients treated with radiotherapy will
develop moderate to severe adverse health effects after treat-
ment, also because of their radiation sensitivity status, which
may affect their quality of life. Modern radiotherapy techni-
ques require frequent imaging for the accurate patient posi-
tioning. The imaging dose adds to the radiotherapy dose to
the normal tissue. In a Finnish study, the maximum cumu-
lative doses from radiotherapy imaging ranged from <20 to
106 mGy. The authors showed that cumulative radiation
organ doses from radiotherapy imaging can vary by a factor
of ten or more, depending on the frequency (e.g. daily vs.
weekly) and the imaging technique used (Siiskonen et al.
2017). With increasing interest in personalized medicine
worldwide, the identification of radiation sensitive and sus-
ceptible individuals using a screening tool would allow to
change the management of these individuals. The goal of
the radiosensitivity biomarker assays elaborated on the basis
of mechanisms of radiosensitivity is to give the radiation
oncologists prior to the beginning of the treatment the
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warning that undesired reactions may occur during or after
the radiation treatment.
In the following, we will illustrate the current situation in
radiation exposure research and conclude with recommen-
dations for the way forward in the research in this field.
2. What is known so far?
2.1. Clinical observations
The aim of radiotherapy is to eradicate the tumor and pre-
vent recurrences with minimal impairment of the quality of
life of the cancer patients. Adverse effects related to ionizing
radiation comprise acute and long-term effects such as vas-
cular damage, heart complications, digestive bowel injury or
fibrosis. The Quantitative Analyses of Normal Tissues
Effects in the Clinics (QUANTEC) (Bentzen et al. 2010;
Jackson et al. 2010; Marks et al. 2010) updated the Emami
data from the early 1990s (Emami et al. 1991) on recom-
mendations how to protect organs to un-attempted effects
of radiotherapy. With advancement of radiotherapy techni-
ques, the rates of side effects decreased over the last deca-
des. For example, the use of the CT scanner allowed
improved delineating the healthy organs as well as the
tumor volumes. Dose-volume histograms (DVHs) enabled
the comparison of dose distributions, but lack spatial
information. To help physicians in the treatment decision,
equivalent uniform dose (EUD) (Niemierko 1997) and
normal tissue complication probability (NTCP) (Lyman
1985; Lyman and Wolbarst 1987; Kutcher et al. 1991)
models were developed and are regularly used (e.g.
Henrıquez and Castrillon 2011; Chaikh et al. 2018; Liang
et al. 2019). However, the algorithmic calculation is not
incorporated in the treatment planning systems.
Concomitantly to these improvements in delineation, com-
plication analysis and improvement of dose calculation,
physicians tried to decrease the dose and irradiated vol-
umes. Hodgkin disease was the main example to keep the
same tumor control and decrease of side effects although
the dose was reduced by one third and no prophylactic
node irradiation was required (Raemaekers et al. 2014;
Aznar et al. 2017; Thomas et al. 2018). New techniques
such as stereotactic irradiation, intensity modulated radi-
ation therapy or use of protons helped to decrease the vol-
ume of irradiated healthy tissue and led to improved dose
distributions. However, there are still ongoing discussions
on long-term effects of new techniques and fractionation
schedules, in particular given the increased life expectancy
of patients and the challenge with re-irradiation.
Furthermore, modern treatment devices are not always
available or affordable.
2.2. Sensitivity
Adverse effects related to ionizing radiation comprise acute
and long-term effects. Radiosensitivity is in particular rele-
vant in the high dose radiation field such as radiotherapy.
Acute effects occur within a few weeks of radiation exposure
in fast proliferating tissue and include dermatitis, mucositis
or hair loss. Long-term effects can emerge years, and even
decades, after radiation exposure and include vascular dam-
age, rectal dysfunction or fibrosis (e.g. Bentzen and
Overgaard 1994; Barnett et al. 2009). The relationship
between acute and late effects still remains unclear.
There are some situations where radiosensitivity has
already been taken into account by radiation oncologists:
a. rare hyper-radiosensitive syndromes like ataxia-telangi-
ectasia homozygotes, Nijmegen breakage syndrome
homozygotes, Fanconi anaemia patients;
b. a few more frequent diseases, for example, neurodege-
nerative diseases, systemic sclerosis, Behc¸et’s disease and
diabetes, that are associated with some degree of
radiosensitivity;
c. paying attention to a family history of cancers because
it could also predispose to radiation-induced second
cancers and clinical hyper-radiosensitivity; and
d. being particularly careful with children with cancer.
In such patients, radiation oncologists commonly adapt
the total dose delivered. Guidelines for such a dose adapta-
tion in radiosensitive patients on the basis of appropriate
assays still need to be elaborated, together with the rules of
clinical follow-up, taking into account the benefit as well as
potential harm for the patients. In case it would be feasible
to elaborate radiation sensitivity on an organ base, it would
be also possible with today’s planning and treatment systems
(intensity modulated radiotherapy, IMRT) to adjust the
application scheme while maintaining the target dose as
close as possible to the prescribed dose. This approach could
even be followed when indications arise for organs of an
individual being more sensitive than expected to ionizing
radiation during the radiation treatment.
It is necessary for the radiation oncologists or the inter-
ventional radiologists to inform the patients of the strategy
of screening of radiosensitivity and radiosusceptibility and of
the consequences in terms of:
 adaptation of radiation therapy dose or the interventional
therapeutic approach and follow-up since the decreased
risk of adverse events may, for example, be associated
with an increased risk of cancer recurrence as a conse-
quence of a delivered dose lower than the conventional
standard protocols;
 a conventional fractionation scheme can be considered
instead of hypofractionation;
 if the risk of adverse effects from radiotherapy is high,
alternative treatment options should be discussed;
 avoid concomitant therapies that increase the risk of
adverse treatment effects (chemotherapy, hormonal ther-
apy) if possible; and
 if the risk of recurrence is low, partial irradiation, for
example, of the breast can be considered.
Markers of radiation sensitivity are urgently required to
adapt the radiotherapy, total dose, dose per fraction,
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technique, beam to personalize radiotherapy. Today, some
biomarker tests are available to detect patients at risk of side
effects (e.g. Azria et al. 2015; Granzotto et al. 2016), but no
consensus was developed for their usefulness and independ-
ent validation is essential.
Also, radiation exposure to low (up to 100 mGy) to mod-
erate dose (100 mGy to 1Gy) may have possible negative
health effects. Cardiac doses from breast cancer radiotherapy
were previously associated with increased cardiovascular
mortality (Darby et al. 2013). Further, there are hints that
low dose exposure might be associated with circulatory dis-
eases (e.g. Darby et al. 2010; Kreuzer et al. 2015) with excess
relative risks per Sv of 0.1–0.2 in a meta-analysis by Little
et al. (2012) and Little (2016), although additional research
better considering potential confounding factors such as
hypertension or body mass index is warranted to confirm
these results (Kreuzer et al. 2015). Doses <0.5Gy to the lens
of the eye were shown to increase the risk of cataracts
(Cucinotta et al. 2001; Neriishi et al. 2007; Worgul et al.
2007; Chodick et al. 2008; Chylack et al, NASA study of
cataract in astronauts (NASCA) 2009; Azizova et al. 2018;
Little et al. 2018), as summarized by Kitahara et al. (2015).
2.3. Susceptibility
A serious health effect of low dose radiation is an increase
in cancer incidence, which has been demonstrated in many
studies, including the Life Span Study of Japanese atomic
bomb survivors (Grant et al. 2017). The extent of this effect
is however not entirely elucidated. Some studies showed a
small increase in cancer risk after low dose exposure; for
example, gamma radiation from natural background has
been suspected to contribute to childhood leukemia as
shown in the UK childhood cancer case–control study
(Brenner et al. 2003; Kendall et al. 2013). Also, occupational
radiation doses (e.g. Muirhead et al. 2009; Leuraud et al.
2015; Richardson et al. 2015) and exposure to radioactive
waste as in the Techa River Cohort in the 1950s (Schonfeld
et al. 2013) were positively associated with increased risk of
solid tumors and non-CLL leukemia.
In the 1980s, the predominant source of radiation expos-
ure (>80%) was from natural background radiation in the
USA. By the mid 2000s, the estimated per capita annual
dose almost doubled from 3.6 mSv to 6.2 mSv, mainly due
to higher medical radiation exposure, in particular from
diagnostic procedures such as CT scans or X-rays (summar-
ized by Kitahara et al. 2015). A number of studies found ele-
vated cancer risks (in particular leukemia and brain tumors)
after multiple CT scans in children and adolescents (e.g.
Einstein 2012; Pearce et al. 2012; Mathews et al. 2013).
Pooled analyses showed that frequency of chromosomal
aberrations and the number of micronuclei in peripheral
blood lymphocytes as biomarker for chromosomal damage
may predict cancer risk (Bonassi et al. 2006; 2008).
It is today not possible to screen all individuals in general
before any medical diagnostic examination involving ioniz-
ing radiation as no reliable marker for susceptibility is
known. Susceptible individuals for whom screening would
be notably relevant include those (especially, children, and
young adults) in whom repeated especially three- or four-
dimensional diagnostic examinations are necessary, for
example, for scoliosis and in particular if the breast is in the
field of view. In such persons, the cumulated dose over the
years may reach a few tens up to 100 mSv.
In these individuals, the identification of radiosusceptibil-
ity could have the consequence to minimize exposures to
ionizing radiation and to favor other modalities of investiga-
tion (echography, MRI) in order to minimize the risk.
A number of studies reported an increased cancer risk
after radiotherapy in organs outside the radiation field (e.g.
Little 2001; Suit et al. 2007; Tubiana 2009; Friedman et al.
2010; Dracham et al. 2018). For example, Berrington de
Gonzalez et al. (2011, 2013) estimated 5 excess secondary
cancers per 1000 patients treated with radiotherapy by
15 years after diagnosis.
2.4. Factors that may play a role in radiation sensitivity
and susceptibility
As mentioned in the MELODI strategic research agenda
(Kreuzer et al. 2018a) and the HLEG report (HLEG 2009),
differences in radiation susceptibility between individuals, or
groups, may relate to genetic constitution (determining sex
and other phenotypic features), but also to other characteris-
tics such as age at exposure, attained age, health status and
comorbidity, epigenetic factors, lifestyle, and co-exposures to
other (non-radiological) stressors.
Age at exposure clearly affects the radiation-induced risk
of certain cancers, such as for instance leukemia (Wakeford
2013) or thyroid cancer (Cardis et al. 2005), for which
exposure at younger ages are associated with higher radi-
ation related-risks (expressed as excess relative risk per Gy).
Whether such patterns apply to all cancer types is, however,
uncertain (UNSCEAR 2013).
Sex may, beyond obvious differences between males and
females in organs and tissues (which can show different
radiation-induced cancer risk per unit dose), influence
radiosusceptibility to cancer in other organs and tissues
through other pathways (e.g. hormonal). Females tend to be
at greater risk of cancer from a given whole-body dose of
radiation than males (Wakeford 2012; Grant et al. 2017).
Epidemiological evidence on the effects of genetic var-
iants is still scarce. Some studies suggest higher radiosus-
ceptibility to breast cancer risk in BRCA mutation carriers
(Pijpe et al. 2012; Colin et al. 2017). In the U.S. Radiologic
Technologists cohort, IL1A A114S significantly modified the
dose-response relationship between cumulative personal
diagnostic radiation and breast cancer risk (Sigurdson et al.
2007). The radiation-associated breast cancer risk also varied
significantly by linked markers in chromosome 5p12 in the
mitochondrial ribosomal protein S30 (MRPS30) gene (Bhatti
et al. 2010). A recent study in uranium miners suggests an
interaction between radon exposure and the genomic region
15q25 on lung cancer risk (Rosenberger et al. 2018).
However, because of the possibility of a chance finding,
these preliminary results call for confirmation in other
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populations. A few genetic markers of late toxicity after
radiotherapy were identified for prostate and breast cancer
so far, such as ATM (e.g. Fachal et al. 2014; Andreassen et
al, International Radiogenomics Consortium (RgC) 2016;
Kerns et al. 2016). There are a few rare hereditary disorders
with increased sensitivity to radiation such as Nijmegen
breakage syndrome or ataxia telangiectasia (e.g. Taylor et al.
1975). However, it is more likely that a number of common
low risk markers account for (at least a proportion of) the
genetic contribution to radiosensitivity, following a poly-
genic model with each genetic marker contributing a small
effect rather than a few contributing high risks as discussed,
for example, by Andreassen and Alsner (2009), Kitahara
et al. (2015), and Andreassen et al, International
Radiogenomics Consortium (RgC) (2016).
Interaction of ionising radiation with co-exposures to
other stressors (e.g. tobacco smoke, heavy metals, medica-
tion) on disease risk is also important (HLEG 2009; Kreuzer
et al. 2018a).
Smoking is among the most studied lifestyle factors in
the radiosusceptibility studies. Studies in uranium miners
internally exposed to radon and its progeny (NRC 1999;
Schubauer-Berigan et al. 2009; Leuraud et al. 2011; Kreuzer
et al. 2018b) and in Mayak workers internally exposed to
plutonium (Gilbert et al. 2013) have reported interactions
ranging from supra-additive to multiplicative on lung cancer
risks, whereas the largest domestic radon studies investigat-
ing this question identified multiplicative interactions
(Krewski et al. 2005; Darby et al. 2006; Turner et al. 2011).
For external radiation exposure, analyses in atomic bomb
survivors data revealed a complex pattern: the excess relative
risk of lung cancer per Gy was higher for low-to moderate
smokers than for non-smoker or for heavy smokers
(Cahoon et al. 2017). It needs to be taken into account that
radiation risks are calculated as a lifetime risk and that
smoking also reduces the lifespan. So there is a competing
risk in a multiplicative risk model because of the higher
background cancers for smokers versus additional radiation
risk due to longer lifespan in never smokers which was
shown in the NASA model (Cucinotta et al. 2012).
Information on effect modification of radiation effects by
other lifestyle aspects such as alcohol consumption or diet-
ary patterns remains limited (e.g. Turner et al. 2011; Grant
et al. 2012).
Very little is known on the joint effects of co-exposures
to radiation and other environmental stressors. Recently,
several studies have begun to investigate such questions, in
line with the rapidly expanding interest for studies of the
human exposome (Wild 2005). This includes effects of co-
exposure to radon and ultraviolet radiation on skin cancer
risks (Vienneau et al, SNC Study Group 2017), radon and
electromagnetic fields from power line on childhood leuke-
mia (Pedersen et al. 2014), radon and urban air pollutants
on lung cancer and leukemia risks (Br€auner et al. 2010;
Turner et al. 2011; Br€auner et al. 2012), radon and asbestos
(Darby et al. 2006), or incense burning (Tse et al. 2011) on
lung cancer risks.
Beyond environmental exposures, interactions with chem-
icals have also been investigated in the field of radiation
therapy studies, where interactions between radiation treat-
ment and chemotherapy (in particular anthracyclines) are an
issue of importance for patient care (e.g. van Nimwegen
et al. 2017).
Also, importantly, radiation exposure of two individuals
under the same radiation setting can result in different dose
patterns (e.g. in terms of absorbed doses to organs and tis-
sues) in these individuals because of inter-individual varia-
tions in their characteristics. Such characteristics notably
include morphology (e.g. body mass index and organ size)
which can influence the relation between external exposure
and organ doses (e.g. Bentzen and Overgaard 1994; Lilla
et al. 2007; Barnett et al. 2009), but also other aspects of
physiology (e.g. breathing rates (Marsh et al. 2014), airway
morphology variability), metabolism, diseases impacting the
function of organs and tissues or even alimentary deficiency
(Cardis et al. 2005), which can modulate the relationship
between intakes of radionuclides and internal dose distribu-
tion through their influence of biokinetics (Schwarz and
Dunning 1982; Klein and Breustedt 2014). As several
physiological characteristics (e.g. height, weight, and breath-
ing rates) are associated with age, dose coefficients can vary
according to age (Kendall and Smith 2005). In case of
internal contamination, some aspects of lifestyle can also
influence the relation between exposure and dose. For
instance, there is greater retention of insoluble forms of plu-
tonium in the pulmonary tissues of smokers (leading to
higher absorbed doses to the lungs) by comparison with
non-smokers (Suslova et al. 2009).
Throughout such influences on dosimetry, individual
characteristics can modulate relationships between exposure
and risk, therefore contributing to radiosusceptibility. This
must be considered, especially, when radiation protection
standards are defined in terms of exposure levels. Therefore,
individual radiosusceptibility can be considered as a function
of exposure and not only dose, and the study of radiosus-
ceptibility should consider the dimensions of dose inhomo-
geneity, radiation quality, and internal versus external
exposures (Kreuzer et al. 2018a).
3. What are the difficulties in radiation
epidemiology?
In 2017, UNSCEAR published its Principles and criteria for
ensuring the quality of the Committee’s reviews of epi-
demiological studies of radiation exposure (UNSCEAR
2017b). Reflecting these principles, we will discuss the major
challenges with epidemiological studies in radiation research
such as power problems when assessing small low dose
effects, bias and confounding, the need for long follow-up
times, heterogeneity in radiation exposure assessment among
studies and in particular with endpoint definitions, collec-
tion of biological material and ethical consequences of indi-
vidual response to ionizing radiation.
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3.1. Power and methodological considerations
As the effect sizes in radiation exposure are often small, in
particular in the low dose field, large sample sizes are
needed. For example, given a cumulative disease incidence
of 0.1, exposed vs. non-exposed of 50% and power of 80%,
about 5500 cases and 5500 controls would be required to
detect a relative risk (RR) of 1.10. If the relative risk is only
1.05 (¼half), then the required sample size would be four-
fold higher. When evaluating differences between subgroups,
this requires even larger sample sizes to achieve adequate
statistical power than analysis of the overall average effect
size because of the smaller subgroups (UNSCEAR 2017a):
Given radiation exposure doubles the risk (RR ¼ 2.0), a
cumulative risk of 0.1, the modifying risk factor is 10%, a
power of 80%, and 50% received radiotherapy, the required
sample size would be 7.261. If the cumulative risk is only
0.01 instead of 0.1, then the required sample size would be
tenfold higher. Very obviously, the required sample size
depends strongly on the risk difference: the larger the con-
trast, the smaller the sample size needed to demonstrate it.
The sample size requirement has major implications for
effect modification analysis. To achieve a reasonable statis-
tical power, large enough numbers of radiation-induced out-
come events are required. This means large sample sizes,
and large effect sizes in relatively frequent endpoints. In
practice, the optimal choice for studies of effect modification
would be common cancer types in large patient cohorts
with high doses followed up at ages when cancer incidence
is high. Children treated for cancer have higher relative risk
coefficients per dose unit, but lower cancer incidence rates
than adult patients. Also, childhood exposures to behavioral
factors that may modify cancer risk from radiation differ
from adult, and they have no occupational exposures, are no
active smokers or alcohol drinkers. Further, comorbidity is
less common in childhood.
It is important to notice that detecting differences in can-
cer risk becomes exceedingly difficult when the radiation-
induced risk diminishes. This means that evaluating effect
modification in low-dose studies is extremely challenging.
Excess risk due to radiation could be observed as additional
cancer cases to those occurring due to other factors
(‘spontaneous’ cases). However, epidemiological studies do
not have enough power to estimate those effects directly,
and the radiation-induced cases cannot be distinguished as
there are no established ‘signatures’ that would reveal radi-
ation as a cause of the malignancy. Therefore, an effect of
radiation can be shown only at group or population level.
Focusing on differences in late effects of high-dose radi-
ation is therefore less difficult. Only when the determinants
of radiation-induced risk have been well established in such
studies, efforts should be directed toward low-dose studies,
where detecting any potential differences in radiation-
induced risk is less likely. However, this presumes that at
higher doses similar processes act as at low doses.
Radiotherapy studies relate to selective populations with pre-
vious cancer and a specific radiation exposure (local, fractio-
nated, etc.), and may thus not be entirely transferable to the
general population and other exposures (potential bias).
The most common cancer types that also have high radi-
ation-induced excess risks include breast, lung, stomach, and
colon cancer. A secondary consideration is the extent of
confounding, that is the impact of other risk factors that
need to be controlled to obtain a valid (unbiased) estimate
of the radiation-induced risk. For instance, smoking is the
major determinant of lung cancer risk, and without accurate
and detailed information on smoking history, the radiation-
induced risk cannot be estimated with confidence. The need
to control for the effect of smoking also decreases the statis-
tical power for assessment of modification due to other fac-
tors. However, information on smoking and other
(potential) risk factors is often not available, although data
on socioeconomic status often provide a reasonable proxy
for it. However, this information should be collected if pos-
sible. On the other hand, for leukemia and thyroid cancer
that have high excess relative risk from radiation, but few
strong and common risk factors (potential confounders)
other than age and sex, this issue might be less problematic.
3.2. Radiation exposure assessment
The radiation exposure assessment is challenging for epi-
demiology. However, individual doses are needed for good
dose–response analysis which are cost and labour intensive
to collect. Especially, when assessing environmental back-
ground radiation exposure, there is usually no dosimetry
information available. For medical radiation exposure, the
calculation of the imaging doses is not trivial and detailed
dosimetry information from physics data (DVHs/Dose-vol-
ume-histograms, DICOMs/Digital imaging and communica-
tions in Medicine) is often not available in patient cohorts.
Low to moderate radiation doses from imaging procedures
also contribute to the total amount of radiation dose and
can have negative health effects. Awareness and optimization
of the diagnostic and interventional radiation exposure (e.g.
imaging dose in image-guided radiotherapy) should be
strengthened. Misclassification of radiation exposure can
yield bias for risk estimates often to the null.
3.3. Uncertainties
One of the biggest challenges are uncertainties. First of all,
there is uncertainty even about the phenomena and con-
cepts, illuminated by the heterogeneity in the definitions
and use of the concepts of sensitivity and susceptibility.
Assessing the modifying factors that affect the probability of
developing a radiation-induced malignancy involves also
uncertainty, as soon as the focus is on anything more com-
plicated than age and sex. Reconstructing exposure history
to co-carcinogens such as smoking history, not to mention
occupational or environmental exposures is also subject to
error. Biological assays always involve some element of
uncertainty, with magnitude highly dependent on the com-
plexity of the method, and reliability is also affected by the
degree of experience of the staff and standardization of the
assay. It is unclear, whether it is possible to apply within
legal considerations if uncertainties remain too large (e.g.
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the proof of a 95% confidence interval that one worker is
more sensitive than another). A study on variability on
organ dose estimated relative uncertainties in the range of
10%–30% (Zvereva et al. 2018). Other publications discussed
various aspects of uncertainties in risk estimates (UNSCEAR
2012b; Fisher and Fahey 2017; Ulanowski et al. 2019)
including competing risks and effective dose.
In order to reduce the uncertainties, it is important to
improve and continue epidemiological studies of health
effects from exposures to ionizing radiation, and to develop
methods to quantify and combine the various sources of
uncertainties, such as impact of population selection, expos-
ure assessment, health outcome assessment, study design,
confounding factors, statistical methods, and model uncer-
tainty and hypothesis of baseline stability over time
(UNSCEAR 2019).
3.4. Study design
To reliably assess adverse health effects after ionizing radi-
ation exposure, long follow-up times over several years (or
even decades) for both low and high dose research are
needed. This includes also long-term funding, often collab-
orative and multinational.
Thorough validation of findings is essential because small
studies can lead to false-positive or false-negative findings.
This is in particular relevant when studying small risk asso-
ciations such as genetic effects. In previous studies, however,
there was often substantial heterogeneity between the studies
in terms of sample size, study design, location, quality of
dose estimates and classification of endpoints (e.g. Kitahara
et al. 2015). In particular, using retrospective study designs
requires careful assessment of potential biases such as selec-
tion bias or recall bias when estimating radiation exposure
doses, for example.
3.5. Heterogeneity in endpoint definitions when
assessing health effects
To reliably assess radiation-related adverse effects, it is
essential to have standardized scoring systems to compare
health effect rates and to identify sensitive subjects. To date,
three scoring systems are commonly used to assess adverse
effects after radiotherapy:
1. the Common Terminology Criteria for Adverse Events
(CTCAE; Trotti 2002);
2. the Radiation Therapy Oncology Group and the
European Organization for Research and Treatment of
Cancer criteria (RTOG/EORTC; Cox et al. 1995); and
3. the Late Effects in Normal Tissue – Subjective,
Objective, Management, Analytic criteria (LENT-
SOMA; Rubin et al. 1995; Seegenschmiedt 1998).
The scoring systems range from grade 0¼ no adverse
effects, grade 1¼mild, grade 2¼moderate, grade 3¼ severe
to grade 4¼ very severe symptoms (and grade 5¼ lethal).
The RTOG/EORTC criteria are more commonly used in
Europe, while CTCAE, published by the National Institute
of Health, now seems to have become the international
standard in classification of cancer treatment related adverse
effects (Zhen et al. 2017). For statistical analysis, toxicity is
often dichotomized as grade 2 or higher. One hint for radio-
sensitivity is that severe adverse reactions occur early during
the course of radiotherapy. Usually, the radiotherapy is then
interrupted before the symptoms reach grade 3 or 4 until
the reactions attenuate. Therefore, it would be useful to also
assess interruptions of radiotherapy due to complications.
When pooling studies that used different scoring systems,
the scoring needs to be harmonized to ensure comparability
across studies (e.g. Hoeller et al. 2003; van der Laan et al.
2008). The Standardized Total Average Toxicity (STAT)
score may be an alternative metric for combining different
toxicities endpoints and enables pooling of data from differ-
ent studies (Barnett et al. 2012).
Due to improvements in radiotherapy techniques (such
as intensity-modulated radiotherapy, image guided radio-
therapy) and treatment planning, the rate of related toxicity
has decreased in the last decades. However, it is still esti-
mated that up to 20% of the cancer patients develop radio-
therapy-related adverse effects of grade 2 or higher, with
about 5% experiencing grade 3 or 4 toxicities (e.g. Marks
et al. 2010). It also should be assessed whether specific late
adverse effects are more common with certain regimens/
techniques such as hypofractionation.
Also, patient reported outcomes are of high relevance to
capture the whole spectrum of radiosensitivity and its
adverse health effects, for example, using the PRO-CTCAE
(Dueck et al. 2015). This involves also (subjective) health-
related quality of life, which can be assessed, for example,
using the EORTC QLQ C30 (Aaronson et al. 1993) or the
FACIT (Functional Assessment of Chronic Illness Therapy,
Cella et al. 1993) questionnaires, as well as disease specific
symptoms. For prostate cancer, for example, these include
EPIC (Expanded prostate cancer index composite, Wei et al.
2000), FACT-P (Functional Assessment of Cancer Therapy
– Prostate, Esper et al. 1997) or EORTC QLQ PR25 (van
Andel et al. 2008) questionnaires.
In oncology, standard definitions of adverse effects are
more internationally accepted. However, similar problems
are faced when comparing studies that are investigating
non-cancer effects such as cataract or cardio-vascular
diseases. In a meta-analysis by Scholz-Kreisel et al. (2017)
on cardiovascular effects after childhood cancer, more than
100 cardiovascular endpoint definitions were found.
Furthermore, consensus is needed on what type of endpoints
can be combined, for example, for cancer types such as leu-
kemia, lymphoma, or brain tumors.
3.6. Collection of biological material
Although it has long been emphasized to include biological
samples in epidemiological studies, there are major obstacles
for the collection. It needs to be defined what to collect, for
example, blood, urine, hair, nails, tissue. In particular for
the latter, the willingness to provide, for example, skin
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samples is limited. Another issue is the timing of sample
collection which should preferably be before radiation
exposure. This is however not always feasible. Many bio-
marker assays were analyzed retrospectively and not vali-
dated in independent populations. Only a few compared
pre- versus post-exposure. If the measured radiosensitivity is
genetically determined though, then it should be less rele-
vant when the sample is taken. Also, the limited sensitivity
and specificity of the assays imply a source of misclassifica-
tion (as discussed in Gomolka et al. 2019 in this Special
Issue). Recently, Schofield and colleagues discussed the issue
of big data in radiation biology including biomaterial
archives (Schofield et al. 2019).
3.7. Ethical issues
When we are faced with the question, whether susceptibility
testing should be offered prior to radiotherapy or employ-
ment in a job involving radiation exposure, a broad evalu-
ation of the issue is needed. Important publications on this
topic include Beauchamp and Childress (2013), Cowley
(2016), Offit and Thom (2007), Perko et al. (2019), Salerno
et al. (2019), ICRP (2018), Brandl and Tschurlovits (2018),
Malone and Z€olzer (2016), and NCRP (2010). The obvious
ethical justification for seeking evaluation of susceptibility is
the potential to reduce adverse effects of radiation exposure
(beneficence), but other ethical issues also need to be con-
sidered including autonomy and justice.
Before susceptibility testing is used outside research pur-
poses, its scientific basis has to be comprehensively elabo-
rated and established. First, the extent and robustness of the
research findings must fulfil the most stringent validity crite-
ria – do we have sound enough knowledge as a basis for
interventions? A real causal effect must be demonstrated,
including confirmation and replication to preclude false-
positive/-negative findings (chance results, serendipity, and
false discovery). For complex diseases, such as any major
non-communicable disease, confounding and other biases
need to be well controlled. Ideally, also adequate under-
standing of mechanism of action is required to improve
plausibility. Second, the interpretation of a test result
should convey a practical meaning and bear some real-life
impact. Susceptibility is nearly always a matter of degree,
not absence versus presence of hazard. The finding
should have a substantial effect on the health outcome in
question, which can be shown in terms of frequencies of
outcomes in those with and without the susceptibility, for
example, P(outcomejexposure and susceptibility) versus
P(outcomejexposure and no susceptibility). This would give
a precise estimate of the excess absolute risk conferred by
the susceptibility.
The ethical principles that need to be evaluated include
autonomy and dignity, including privacy and confidentiality,
justice, as well as beneficence and non-maleficence (e.g. Cho
et al, Authors on behalf of ICRP 2018).
Besides firmly established scientific evidence, an equally
important prerequisite for susceptibility testing is that it
should benefit the person, and those benefits should out-
weigh any harms.
Justice means that people should be treated equally,
unless there is a legitimate and justifiable reason for differ-
ent treatment. Generally, characteristics that are outside the
control of people themselves such as age, gender or ethnicity
are not legitimate results for unequal treatment. This clearly
applies also to genetic traits. All of these features are poten-
tial determinants of susceptibility and hence relevant here.
If it is established that a certain constitution or trait ren-
ders some people more liable to develop disease following
radiation exposure, those people are vulnerable, and it is not
only a medical issue, but bears also major ethical and social
implications. There is also a clear potential for misuse of
susceptibility information, for example, stigma and discrim-
ination. In the social sphere, such information could limit
opportunities at work, availability of insurance, result in dis-
crimination and stigmatization. Psychologically such vulner-
ability can induce fear, anxiety, fatalism, or loss of
self-efficacy.
Autonomy and informed consent entail the right to know
but also the right to remain in ignorance. It should be up to
the person to decide whether he or she wants to know the
susceptibility status. A further issue is the potential impact
of other people such as family members in the case of her-
editary traits.
Informed consent requires provision of information, indi-
vidual assessment of capacity for judgment and decision-
making, and opportunity to consider and decide. Besides
facts, the decisions should be compatible with the person’s
own values and priorities relevant for the context.
An established framework for application should exist to
guide practice. Decision-making should not take place only
on a case-by-case basis, but regulation to protect the subject
is needed. Such guidelines should be developed by multidis-
ciplinary expert groups, probably under auspices of govern-
mental organizations or professional societies. Also, clear
options should be defined as the basis of decision-making,
whether related to the susceptibility of the effects of radi-
ation at work or in therapeutic applications. Alternative
course of action should be clearly outlined with reduced
radiation exposure and pertinent risks (as well as potential
loss of treatment benefits). Guidance or counselling with
sufficient expertise about the nature and meaning of suscep-
tibility should be available to support decision-making both
before and after susceptibility testing. Just providing infor-
mation about existence of susceptibility is not ethically justi-
fiable and can be regarded as abandonment.
Besides the ethical issues related to the development of
this type of predictive medicine, the identification of radio-
sensitivity/radiosusceptibility also raises the legal issue who
is responsible for the results of the assay(s) especially, if they
include the exposure to ionizing radiation of a tissue sample
(lymphocytes, fibroblasts… ). One can imagine that clinical
laboratory technologists would be authorized to practice for
such assays. Additional questions regarding the legal as well
as the ethical aspects arise if artificial intelligence would be
used to evaluate assays or other markers, and such results
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should be used for personalizing diagnostic approaches and/
or therapeutic applications of IR.
The ethical aspects of the individual response evaluation
to ionizing radiation are also covered in a separate paper by
Kalman and Oughton (2019) in this Special Issue.
4. How to overcome these difficulties in the next
years: recommendations for the way forward in
radiation research
4.1. Need for large prospective cohort studies
These prospective cohorts (with other epidemiological
research questions) need sufficient long-term follow-up and
sufficient sample size because radiation-related effects often
emerge years after exposure. Adequate exposure measure-
ment, standardized health effects assessment, repeated meas-
urements and identification of sources of uncertainty is
needed. Realistic drop-out rates need to be considered.
Small studies can lead to false-positive/false-negative find-
ings. Therefore, international collaborations are highly
needed, including international funding opportunities for
long-term follow-up which is very limited at the moment.
The data sources should be made accessible to the research
community.
4.2. Find existing radiation research cohorts
Existing European cohorts for radiation epidemiology
research can be identified via the newsletter (http://www.
concert-h2020.eu/en/Concert_info/Access_Infrastructures/
Bulletins) and the http://www.concert-infrastructures.eu/
home website from the CONCERT initiative, for example.
In addition, there are several cohorts on childhood cancer
patients (e.g. Hawkins et al. 2008; Rugbjerg et al. 2014;
Schwartz et al. 2014; Asdahl et al. 2015; Winther et al. 2015;
Teepen et al. 2017; Grabow et al. 2018). Their follow-up for
subsequent neoplasms is a promising approach to study
effects and effect modification in organs exposed to both
high and low doses. Nevertheless, the effect of non-radiation
risk factors underlying the first tumor and the effects of
chemotherapy and other treatment for the first primary
tumor need to be controlled for.
There is a number of radiotherapy patient cohorts estab-
lished worldwide, for example, approachable through the
Radiogenomics Consortium with members at more than 100
institutions (RgC; West et al. 2010; Rosenstein et al,
Radiogenomics Consortium 2014; https://epi.grants.cancer.
gov/radiogenomics/) or the RTOG/EORTC trials.
Biosamples might be available for some radiotherapy cohorts
such as the COPERNIC cohort (Granzotto et al. 2016).
Further in 2013, a large international cohort with over 4400
RT patients with prospective and standardized data collec-
tion, the REQUITE project (www.requite.eu), was estab-
lished in Europe and the USA with at least two years of
follow-up (e.g. West et al. 2014; Seibold et al. 2019).
A systematic review on existing cohorts for radiation
research is encouraged and currently being undertaken by
Cardis et al. based on a DoReMi survey. The heterogeneity
of the study populations in these studies needs to be
investigated. Challenges in combining data from various
sources include data harmonization, data quality and data
handling.
4.3. Use data from well-defined cohorts with good
exposure assessment and biological material
already collected
Many cohorts have been established during the last years in
Europe and elsewhere such as the UK biobank,
Scandinavian biobanks such as the Biobank of Eastern
Finland, CONSTANCES in France, the German National
Cohort (NAKO), the Gutenberg Heart Study and many
others. Although not intended for radiation research, some
of them have already collected biological material and some
may even have basic information on radiation exposure.
Smart designs, such as nested case-control studies in a
defined cohort and use of record linkage (e.g. with publicly
available environmental databases) should be developed to
use this large valuable source of data. It should also be
assessed which quality of dose reconstruction and which
prevalence of radiation exposure can be expected.
4.4. Focus on study quality with standardized data
collection and reporting
Endpoints to be studied for radiosensitivity and radiosus-
ceptibility need to be clearly defined upfront using standar-
dized endpoint definitions. Adverse effects from ionizing
radiation should be routinely documented using a standar-
dized scoring system. Toxicity evaluation at different time
points is preferable to detect undesired effects early. The
radiation quality needs to be taken into account. When pub-
lishing the study findings, existing reporting guidelines such
as CONSORT (Begg et al. 1996), PRISMA (Moher et al,
PRISMA-P Group 2015), STROBE (von Elm et al, STROBE
Initiative 2014), or STROGAR (Kerns et al. 2014) should
be applied.
For radiotherapy cohorts: If possible, the situation before
radiotherapy should be documented and interruptions of
radiotherapy due to complications should be recorded as
well. Also untreated similar locations such as the contralat-
eral breast could be compared with. Both medical doctor
diagnosed and patient self-reported outcomes should be col-
lected. Both objective and subjective assessment like quality
of life are of relevance. Information on secondary cancers
after radiotherapy should be collected. Comprehensive
radiotherapy dosimetry data is of great importance for
effects at remote sites from the target tissue. Radiotherapy
techniques have improved over time and keeping the old
software and hardware for evaluating physics data of long-
term studies is needed. Photos of the irradiated organ pre-
and post-radiotherapy can be compared to assess cosmesis.
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4.5. Improve statistical analysis
Power calculations are crucial: Evaluating differences
between subgroups requires substantially large sample sizes.
Statistical analysis should be conducted based on a statistical
analysis plan. Multivariate models should take known influ-
encing factors into account that may explain variation in
radiation response. It should be clear which results are
hypothesis driven vs. exploratory. To avoid false-positive
and false-negative findings, adjustment for multiple testing
and (if possible) validation of findings in independent popu-
lations should be aimed for. Thorough assessment of any
type of bias, confounding and misclassification should be
part of the statistical analysis.
4.6. Cooperation between radiobiology and
epidemiology
Identify which types of samples are most relevant for a bio-
marker assay of individual response to radiation (e.g. blood,
tissue, saliva, and urine). If possible, sample collection
should cover both pre- and post-radiation exposure. Take
into account logistic issues of sample collection (e.g. timing,
transport, skin tissue, fresh sample, etc.). Develop and valid-
ate a biomarker (and/or signature) for radiation exposure,
early and late health effects. Assess gene-environment inter-
actions with radiation exposure. It is likely that a combin-
ation of assays is needed rather than one single test to assess
radiosensitivity (see also Gomolka et al. in this Special
Issue). It is encouraged to make use of experienced labora-
tory networks (e.g. RENEB) with inter-comparisons, other
established infrastructures and outside-the-field expertise as
stated in the MELODI Strategic Research Agenda 2018
(Averbeck et al. 2018).
4.7. Take into account consequences of radiosensitivity
and radiosusceptibility
Develop fast, affordable and reliable tests for the identifica-
tion of radiosensitive/radiosusceptible individuals and
come up with recommendations and guidelines for the
implementation and use. For acceptance, the risk assess-
ment tools needed to be easily useable and interpretable,
such as nomograms. For a more detailed discussion on eth-
ical aspects, please see Kalman and Oughton (2019) in this
Special Issue.
5. Summary
There remains a long way ahead before a somewhat more
individualized approach will be implemented in the radi-
ation protection system, but discussions towards individual-
ized strategies are useful, such as for protection of medical
patients, emergency workers, and astronauts, among which
medicine will lead the way. Strategies to incorporate the
individualized approach need to be considered, along with
further developments of scientific knowledge and ethical
foundations.
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